Aurobindo Pharma Ltd Financial Statement
*All values are in Rs. Cr
| Particulars | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|
| Revenue | 2,947.25 | 2,525.41 | 3,017 |
| Operating Expense | 2,103.71 | 1,961.16 | 2,119.24 |
| Net Profit | 537.53 | 329.04 | 578.67 |
| Net Profit Margin | 18.24 | 13.03 | 19.18 |
| Earning Per Share | 9.21 | 5.62 | 9.88 |
| EBIDTA | 845.75 | 566.71 | 904.21 |
| Effective Tax Rate | 22.34 | 21.21 | 23.13 |
| Particulars | Sep 2024 |
|---|---|
| Revenue | 2947.25 |
| Operating Expense | 2103.71 |
| Net Profit | 537.53 |
| Net Profit Margin | 18.24 |
| Earning Per Share | 9.21 |
| EBIDTA | 845.75 |
| Effective Tax Rate | 22.34 |
Invest in Aurobindo Pharma Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| Total Revenue Annual | 10,645.64 | 8,457 | 11,287.14 |
| Operating Expenses Annual | 8,421.60 | 6,952.09 | 9,813.74 |
| Operating Profit Annual | 2,894.14 | 1,933.77 | 2,069.68 |
| Interest Annual | 182.60 | 74.58 | 16.94 |
| Depreciation | 236.72 | 219.12 | 411.53 |
| Net Profit Annual | 1,900.10 | 1,242.17 | 1,454.71 |
| Tax Annual | 502.82 | 388.82 | 182.77 |
| Particulars | Mar 2024 |
|---|---|
| Total Revenue Annual | 10,645.64 |
| Operating Expenses Annual | 8,421.60 |
| Operating Profit Annual | 2,894.14 |
| Interest Annual | 182.60 |
| Depreciation | 236.72 |
| Net Profit Annual | 1,900.10 |
| Tax Annual | 502.82 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| Cash Flow at the Beginning | 357.13 | 51.13 | 383.58 |
| Cash Flow from Operations | 1,714.80 | 1,816.17 | 3,726.71 |
| Cash Flow from Investing | -151.58 | -3,229.65 | -1,614.54 |
| Cash Flow from Financing | -1,837.03 | 1,719.48 | -2,447.54 |
| Cash Flow at the End | 83.32 | 357.13 | 48.21 |
| Particulars | Mar 2024 |
|---|---|
| Cash Flow at the Beginning | 357.13 |
| Cash Flow from Operations | 1,714.80 |
| Cash Flow from Investing | -151.58 |
| Cash Flow from Financing | -1,837.03 |
| Cash Flow at the End | 83.32 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| PBDIT Margin (%) | 27.19 | 22.87 | 18.34 |
| PBIT Margin (%) | 24.79 | 19.99 | 14.66 |
| PBT Margin (%) | 24.65 | 19.72 | 13.79 |
| Net PROFIT Margin (%) | 18.36 | 14.51 | 12.89 |
| Return On Networth / Equity (%) | 10.35 | 6.98 | 8.81 |
| Return On Networth /Employed (%) | 11.74 | 8.18 | 8.49 |
| Return On Assets (%) | 8.63 | 5.95 | 7.48 |
| Total Debt / Equity (X) | 0.19 | 0.17 | 0.18 |
| Asset Turnover Ratio (%) | 0.47 | 0.41 | 0.58 |
| Particulars | Mar 2024 |
|---|---|
| PBDIT Margin (%) | 27.19 |
| PBIT Margin (%) | 24.79 |
| PBT Margin (%) | 24.65 |
| Net PROFIT Margin (%) | 18.36 |
| Return On Networth / Equity (%) | 10.35 |
| Return On Networth /Employed (%) | 11.74 |
| Return On Assets (%) | 8.63 |
| Total Debt / Equity (X) | 0.19 |
| Asset Turnover Ratio (%) | 0.47 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| Fixed Assets Annual | 2,419.13 | 3,687.50 | 3,585.83 |
| Total Current Assets Annual | 7,239.13 | 9,964.99 | 9,835.11 |
| Non Current Assets Annual | 17,914.85 | 15,093.82 | 11,765.84 |
| Total Shareholders Funds Annual | 19,722.82 | 18,034.03 | 17,117.34 |
| Total Assets Annual | 25,153.98 | 25,058.81 | 21,600.95 |
| Particulars | Mar 2024 |
|---|---|
| Fixed Assets Annual | 2,419.13 |
| Total Current Assets Annual | 7,239.13 |
| Non Current Assets Annual | 17,914.85 |
| Total Shareholders Funds Annual | 19,722.82 |
| Total Assets Annual | 25,153.98 |
EPS (INR)
Expected
14.07
Reported
14.00
Surprise
-0.50%
Jun 2024
EPS beaten by -0.50%
Mar 2024
EPS beaten by 0.00%
Dec 2023
EPS beaten by 0.00%
